BET inhibitors in cancer therapeutics: a patent review

References

• [ cited 2015 Dec 29]. Available from: http://www.who.int/cancer/en/.
   Google Scholar
• Balis FM. Evolution of anticancer drug discovery and the role of cell-based screening. J Natl Cancer Inst. 2002;94(2):78–79.
   PubMedGoogle Scholar
• Vidler LR, Brown N, Knapp S, et al. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem. 2012;55(17):7346–7359.
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014;13(5):337–356.
   PubMed Web of Science ®Google Scholar
• Muller S, Filippakopoulos P, Knapp S. Bromodomains as therapeutic targets. Expert Rev Mol Med. 2011;13:e29.
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012;149(1):214–231.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529–533.
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904–917.
   PubMed Web of Science ®Google Scholar
• Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524–528.
   PubMed Web of Science ®Google Scholar
• Banerjee C, Archin N, Michaels D, et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol. 2012;92(6):1147–1154.
   PubMed Web of Science ®Google Scholar
• Zhu J, Gaiha GD, John SP, et al. Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep. 2012;2(4):807–816.
   PubMed Web of Science ®Google Scholar
• Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468(7327):1119–1123.
   PubMed Web of Science ®Google Scholar
• Denis GV. Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation. Discov Med. 2010;10(55):489–499.
   PubMed Web of Science ®Google Scholar
• Anand P, Brown JD, Lin CY, et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell. 2013;154(3):569–582.
   PubMed Web of Science ®Google Scholar
• Haldar SM, McKinsey TA. BET-ting on chromatin-based therapeutics for heart failure. J Mol Cell Cardiol. 2014;74:98–102.
   PubMed Web of Science ®Google Scholar
• Sun Y, Huang J, Song K. BET protein inhibition mitigates acute myocardial infarction damage in rats via the TLR4/TRAF6/NF-κB pathway. Exp Ther Med. 2015;10(6):2319–2324.
   PubMed Web of Science ®Google Scholar
• Matzuk MM, McKeown MR, Filippakopoulos P, et al. Small-molecule inhibition of BRDT for male contraception. Cell. 2012;150(4):673–684.
   PubMed Web of Science ®Google Scholar
• Bisgrove DA, Mahmoudi T, Henklein P, et al.. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci USA. 2007;104(34):13690–13695.
   PubMed Web of Science ®Google Scholar
• Jang MK, Mochizuki K, Zhou M, et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005;19(4):523–534.
   PubMed Web of Science ®Google Scholar
• Yang Z, Yik JH, Chen R, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005;19(4):535–545.
   PubMed Web of Science ®Google Scholar
• Gehling VS, Hewitt MC, Vaswani RG, et al. Discovery, design, and optimization of isoxazole azepine BET inhibitors. ACS Med Chem Lett. 2013;4(9):835–840.
   PubMed Web of Science ®Google Scholar
• Xue X, Zhang Y, Liu Z, et al.. Discovery of benzo[cd]indol-2(1H)‑ones as potent and specific BET bromodomain inhibitors: structure-based virtual screening, optimization, and biological evaluation. J Med Chem. 2015;in press. doi:10.1021/acs.jmedchem.5b01511.
   Web of Science ®Google Scholar
• Raux B, Voitovich Y, Derviaux C, et al.. Exploring selective inhibition of the first bromodomain of the human bromodomain and extra-terminal domain (BET) proteins. J Med Chem. 2015;in press. doi:10.1021/acs.jmedchem.5b01708.
   Web of Science ®Google Scholar
• Ran X, Zhao Y, Liu L, et al. Structure-based design of γ-carboline analogues as potent and specific BET bromodomain inhibitors. J Med Chem. 2015;58(12):4927–4939.
   PubMed Web of Science ®Google Scholar
• Baud MGJ, Lin-Shiao E, Zengerle M, et al.. New synthetic routes to triazolo-benzodiazepine analogues: expanding the scope of the bump-and-hole approach for selective bromo and extra-terminal (BET) bromodomain inhibition. J Med Chem. 2015;in press. doi:10.1021/acs.jmedchem.5b01135.
   PubMed Web of Science ®Google Scholar
• Zhang G, Smith SG, Zhou M-M. Discovery of chemical inhibitors of human bromodomains. Chem Rev. 2015;115(21):11625–11668.
   PubMed Web of Science ®Google Scholar
• Smith SG, Zhou -M-M. The bromodomain: a new target in emerging epigenetic medicine. ACS Chem Biol. 2015; in press. doi:10.1021/acschembio.5b00831.
   Google Scholar
• Smith SG, Sanchez R, Zhou M-M. Privileged diazepine compounds and their emergence as bromodomain inhibitors. Chem Biol. 2014;21(5):573–583.
   PubMed Web of Science ®Google Scholar
• French CA, Miyoshi I, Kubonishi I, et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003;63(2):304–307.
   PubMed Web of Science ®Google Scholar
• French CA, Ramirez CL, Kolmakova J, et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene. 2008;27(15):2237–2242.
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, et al.. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067–1073.
   PubMed Web of Science ®Google Scholar
• Glaxo Smith Kline. A study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK525762 in subjects with NUT midline carcinoma (NMC) and other cancers. Bethesda (MD): U. S. National Institutes of Health; 2016. (ClinicalTrials.gov, NCT01587703).
   Google Scholar
• Glaxo Smith Kline. A dose escalation study to investigate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies. Bethesda (MD): U.S. National Institutes of Health; 2016. (ClinicalTrials.gov, NCT01943851).
   Google Scholar
• Wyspianska B, Bannister A, Barbieri I, et al. BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. Leukemia. 2014;28(1):88–97.
   PubMed Web of Science ®Google Scholar
• Oncoethix GmbH. A phase I, dose-finding study of the bromodomain (Brd) inhibitor OTX015/ MK-8628 in hematologic malignancies (MK-8628-001). Bethesda (MD): U.S. National Institutes of Health; 2016. (ClinicalTrials.gov, NCT01713582).
   Google Scholar
• Oncoethix GmbH. A dose-finding study of OTX105/MK-8628, a small molecule inhibitor of the bromodomain and extra-terminal (BET) proteins, in adults with selected advanced solid tumors (MK-8628-003). Bethesda (MD): U.S. National Institutes of Health; 2016. (ClinicalTrials.gov, NCT02259114).
   Google Scholar
• Bonetti P, Ponzoni M, Tibiletti MG, et al. The BRD-inhibitor OTX015 shows pre-clinical activity in diffuse large B-cell lymphoma (DLBCL). Eur J Cancer. 2012;48(6):163.
   Google Scholar
• Tensha Therapeutics. A dose escalation and cohort expansion study of TEN-010 in patients with acute myeloid leukemia and myelodysplastic syndrome. Bethesda (MD): U.S. National Institutes of Health; 2015. (ClinicalTrials.gov, NCT02308761).
   Google Scholar
• Tensha Therapeutics. A two part, multicenter, open-label study of TEN-010 given subcutaneously. Bethesda (MD): U.S. National Institutes of Health; 2015. (ClinicalTrials.gov, NCT01987362).
   Google Scholar
• Constellation Pharmaceuticals. A phase 1 study evaluating CPI-0610 in patients with progressive lymphoma. Bethesda (MD): U.S. National Institutes of Health; 2016. (ClinicalTrials.gov, NCT01949883).
   Google Scholar
• Constellation Pharmaceuticals. A phase 1 study evaluating CPI-0610 in patients with previously treated multiple myeloma. Bethesda (MD): U.S. National Institutes of Health; 2016. (ClinicalTrials.gov, NCT02157636).
   Google Scholar
• Constellation Pharmaceuticals. A phase 1 study evaluating CPI-0610 in patients with acute leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasms, and myelofibrosis. Bethesda (MD): U.S. National Institutes of Health; 2016. (ClinicalTrials.gov, NCT02158858).
   Google Scholar
• Lejeune P, Sugawara T, Gelato KA, et al. BAY 1238097, a novel BET inhibitor with strong efficacy in haematological tumor models. In: proceedings of the 106th annual meeting of the American Association for Cancer Research, Philadelphia, PA April 18-22, 2015. Cancer Res. 2015;75(15):3524.
   Google Scholar
• Garnier J-M, Sharp PS, Burns CJ. BET bromodomain inhibitors: a patent review. Expert Opin Ther Pat. 2014;24(2):185–199.
   PubMed Web of Science ®Google Scholar
• Mitsubishi Tanabe Pharma Corporation. Antitumor agent. WO2009084693. 2009.
   Google Scholar
• Bayer Pharma AG. 6-substituted 2,3-benzodiazepines. WO2015121226. 2015.
   Google Scholar
• Bayer Pharma AG. 6,9-disubstituted 1-phenyl-3H-2,3-benzodiazepines and their use as bromodomain inhibitors. WO2015121227. 2015.
   Google Scholar
• Bayer Pharma AG. 9-substituted 2,3-benzodiazepines. WO2015121230. 2015.
   Google Scholar
• Bayer Pharma AG. 1-phenyl-3H-2,3-benzodiazepines and their use as bromodomain inhibitors. WO2015121268. 2015.
   Google Scholar
• Kainos Medicine, Inc. Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer. WO2015156601. 2015.
   Google Scholar
• Oncoethix SA. A BET-BRD inhibitor represents a novel agent for Alk positive anaplastic large cell lymphoma. WO2015018520. 2015.
   Google Scholar
• Oncoethix SA. BET bromodomain inhibitor shows synergism with several anticancer agents in preclinical models of diffuse large B-cell lymphoma (DLBCL). WO2015018522. 2015.
   Google Scholar
• Oncoethix SA. A novel BET-BRD inhibitor for treatment of solid tumors. WO2015018523. 2015.
   Google Scholar
• Oncoethix GmbH. A study assessing tOTX015 in combination with Azacitidine (AZA) or AZA single agent in patients with newly-diagnosed acute myeloid leukemia (AML) not candidate for Standard Intensive Induction Therapy (SIIT). Bethesda (MD): U.S. National Institutes of Health; 2015. (ClinicalTrials.gov, NCT02303782).
   Google Scholar
• Oncoethix GmbH. A trial with dose optimization of OTX015 in recurrent glioblastoma multiforme (GBM) patients (OTX015_107). Bethesda (MD): U.S. National Institutes of Health; 2015. (ClinicalTrials.gov, NCT02296476).
   Google Scholar
• Kyorin Pharmaceutical Co., Ltd. Heterocyclic compounds. WO2015129927. 2015.
   Google Scholar
• Novartis AG. Pyrrolopyrrolone derivatives and their use as BET inhibitors. WO2015075665. 2015.
   Google Scholar
• Incyte Corporation. Bicyclic heterocycles as BET protein inhibitors. WO2015081189. 2015.
   Google Scholar
• Incyte Corporation. Bicyclic heterocycles as BET protein inhibitors. WO2015081203. 2015.
   Google Scholar
• Incyte Corporation. Tricyclic heterocycles as BET protein inhibitors. WO2015095492. 2015.
   Google Scholar
• Incyte Corporation. 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4c]pyridin-7(6H)-ones as inhibitors of BET proteins. WO2015164480. 2015.
   Google Scholar
• Bayer Pharma AG. Modified BET-protein-inhibiting dihydroquinoxalinones and dihydropyridopyrazinones. WO2015004075. 2015.
   Google Scholar
• Bayer Pharma AG. Substituted dihydropyrido[3,4-B]pyrazinones as dual inhibitors of BET proteins and polo-like kinases. WO2015011084. 2015.
   Google Scholar
• Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors. WO2015002754. 2015.
   Google Scholar
• Chung C, Coste H, White JH, et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011;54(11):3827–3838.
   PubMed Web of Science ®Google Scholar
• Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors. WO2015004533. 2015.
   Google Scholar
• Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors. WO2015004534. 2015.
   Google Scholar
• Aurigene Discovery Technologies Limited. Bicyclic heterocyclic derivatives as bromodomain inhibitors. WO2015104653. 2015.
   Google Scholar
• The Regents of the University of Michigan. 9H-pyrimido[4,5-B]indoles and related analogs as bromodomain inhibitors. WO2015131005. 2015.
   Google Scholar
• Forma Therapeutics, Inc. Tetrahydroquinoline compositions as BET bromodomain inhibitors. WO2015074064. 2015.
   Google Scholar
• Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors. WO2015015318. 2015.
   Google Scholar
• SignalRx Pharmaceuticals, Inc. Novel heterocyclic compound classes for signalling modulation. US20150315207. 2015.
   Google Scholar
• Icahn School of Medicine at Mount Sinai. Cyclic vinylogous amides as bromodomain inhibitors. WO2015031824. 2015.
   Google Scholar
• Forma Therapeutics, Inc. Benzopiperazine compositions as BET bromodomain inhibitors. WO2015074081. 2015.
   Google Scholar
• Medivation Technologies, Inc. Aromatic compounds, compositions and uses thereof. WO2015184405. 2015.
   Google Scholar
• University of Dundee. Enzymes functional probes. WO2015079259. 2015.
   Google Scholar
• Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders. WO2011143669. 2011.
   Google Scholar
• Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using Bromodomain and Extra-Terminal (BET) protein inhibitors. WO2015070020. 2015.
   Google Scholar
• Infinity Pharmaceuticals, Inc. Combination therapies. WO2015160986. 2015.
   Google Scholar
• The Brigham and Women’s Hospital, Inc.; President and Fellows of Harvard College. The NSD3 inhibitors for treatment of cancers. WO2015112809. 2015.
   Google Scholar
• Palacky University, Olomouc. Method of predicting the tumor response to DNA methylation inhibitors and alternative therapeutic regimen for overcoming resistance. WO2015144102. 2015.
   Google Scholar
• INSERM (Institut National De La Santé Et De La Recherche Medicale), Institut Jean Paoli and Irene Calmettes, Université D’Aix Marseille, Centre National De La Recherche Scientifique (CNRS). Methods for the treatment of T-cell acute lymphoblastic leukemias. WO2015144636. 2015.
   Google Scholar
• Constellation Pharmaceuticals, Inc. Expression levels of BCL-xL, BCL2, BCL-w, and BAD and cancer therapies. WO2015153871. 2015.
   Google Scholar